Burlington, Ontario–(Newsfile Corp. – December 11, 2024) – Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC Pink: MUSLF) (FSE: 93X) (the “Company” or “Promino”) is pleased to present a progress report highlighting the Company’s major milestones and developments achieved in the second half of 2024.
Promino Chief Executive Officer Vito Sanzone said, “This period has been a transformational one for Promino, as we have made significant strides expanding our product offering, establishing a global presence, and enhancing our operational infrastructure. These achievements have resulted in recording revenue for six consecutive months for the first time since 2022, and position us for continued growth and commercialization success in the coming year. We enter 2025 positioned to succeed in our key markets, especially with the marketing of our brands for lean muscle support for consumers using GLP-1 drugs for weight loss.”
Strategic Milestones and Key Developments
Financial and Market Outlook
Promino’s performance has been buoyed by robust product placements, strategic partnerships, and an expanding global market. With a strengthened DTC infrastructure and growing retailer partnerships, the Company is poised for continued revenue growth in late 2024 and into 2025. The upcoming launch of RTD products, along with exploration into new market segments will enhance our ability to capture greater market share across the global nutritional and wellness industry.
Conclusion
Promino is on a strong growth trajectory, underpinned by strategic product innovations, key retail partnerships, and a world-class advisory team. Our dedication to delivering premium nutritional solutions that address diverse health needs is driving momentum in the marketplace. As we move into 2025, we are excited by the opportunities ahead and are confident that the foundation we have built will enable us to continue delivering value for our shareholders.
About Promino
Promino is an innovative and research driven Canadian nutraceutical company specializing in the development of patented and science-based products for the global consumer packaged goods market, with a portfolio focused specifically on muscle health. Promino’s lead product, Rejuvenate™, is a patented proprietary formulation that is clinically proven to assist in the building, rebuilding, restoration and rejuvenation of natural muscle mass. Promino also offers Promino™, an elite performance supplement for both professional and amateur athletes to accelerate muscle recovery, build strength and accelerate recovery from injury. Promino was founded in 2015 and is located in Burlington, Ontario.
To learn more about Promino, visit http://www.drinkpromino.com.
Forward-Looking Statements
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. All statements that address activities, events, or developments that the Company expects or anticipates will, or may, occur in the future, are forward-looking statements, including statements regarding the Company’s business prospects, potential growth in the functional beverage market, future trends, plans and strategies. In some cases, forward looking statements are preceded by, followed by, or include words such as “may”, “will,” “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “anticipates”, “continues”, or the negative of those words or other similar or comparable words. In preparing the forward-looking statements in this news release, the Company has applied several material assumptions, including, but not limited to, that protein supplement market growth will continue as anticipated by the Company, and that general business and economic conditions will not change in a materially adverse manner. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
For further information about Promino:
Vito Sanzone, CEO, vsanzone@drinkpromino.com, 289-348-1970 ext. 222
Marc Charbin, Investor Relations, marc.charbin@loderockadvisors.com, 416-467-5229
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233230
Scottsdale, Arizona--(Newsfile Corp. - December 12, 2024) - Sibannac, Inc. (OTC Pink: SNNC), a visionary…
The Brooklyn-based salon, with locations in Brooklyn Heights and Carroll Gardens, is proud to help…
Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3…
MCLEAN, VA / ACCESSWIRE / December 12, 2024 / Dr. Amir Bajoghli recently had the…
Celebrating a Culture of Collaboration and a Mission to Save Lives Through Data SAN DIEGO,…
CELLEV8 Launches First Post-GLP-1 Gummy Supplement: "SlimCell™" with Clinically Proven Ingredients to Compliment GLP-1 WELLINGTON,…